TrialNature communications2024

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.

Joseph F Standing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.